Jul 04, 2025
The GvHD drugs treatment landscape is undergoing a dynamic transformation, driven by a wave of innovation aimed at improving patient outcomes and quality of life. Once dominated by steroids and broad immunosuppressants, the field is now witnessing a surge in targeted therapies, cellular approaches, and novel biolog...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper